Insider buying last 90 days
No open-market insider purchases were filed for GH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Guardant Health closed at $158.79 on 9 November 2026, +5.2% on the day. The price sits between the 50-day ($169.26) and 200-day ($131.95) moving averages, inside a 52-week range of $74.55 to $191.05. The GekkoIndex reads 66.3, in the Accumulation zone, up 9.5 points over five sessions. Gekko Fair Value is $182.49, so the price is 13% below it.
The next earnings report is due on 18 February 2027, 95 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 11.7% across the report. Smart-money activity over the last 90 days includes 1 Congress purchase and 0 sales. Over the last 30 days there were 2 unusual options signals. Seasonally, the next 20 trading days from this point averaged +8.8% over the last 5 years, rising in 3 of them.
19 firms rate the stock: 19 buy, 0 hold and 0 sell, with a consensus target of $202.24. A typical daily move is about 6.7%, and a typical 20-day move about 11.1%. On the swing-trade checklist, 4 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 9, 2026 close.
Guardant Health scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $151.70 sits between the 50-day ($168.65) and 200-day ($132.79) averages, or the averages disagree.
See the chart67.1, Accumulation
Reading 67.1 is in the Accumulation zone.
See the GekkoIndex16.4% below
Price is 16.4% below Gekko Fair Value (more than 5% below).
See fair valueMixed
Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 2 unusual options signals.
See smart moneyReports in 95 days
Next report Feb 18, 2027, 95 days away — outside a typical 20-trading-day hold.
See earnings+3.2% on average
From this point in the calendar, the next 20 trading days averaged +3.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Guardant Health closed at $151.70 on Nov 13, 2026, +55.0% over the past year, inside a 52-week range of $74.55 to $191.05.
Use the left and right arrow keys to read daily values.
Put GH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Guardant Health focuses on precision oncology, offering blood-based diagnostic tests along with data sets and analytical tools for patients dealing with cancer, both in the United States and abroad. Its work centers on liquid biopsy testing, with products such as Guardant360 and GuardantOMNI aimed at people with advanced-stage disease, and the Guardant Reveal Test supporting treatment decisions for those in earlier stages. The company also markets Guardant360 for tissue genotyping and a coronavirus detection test called Guardant-19.
Beyond its diagnostic products, Guardant Health runs GuardantINFORM, a research platform built on genomic data gathered from liquid biopsies of advanced cancer patients, and is developing tools including LUNAR-2 for early colorectal cancer detection and GuardantConnect, a platform meant to connect patients with relevant clinical trials. The company also works with biopharmaceutical firms and medical institutions, providing services such as companion diagnostic development, regulatory support, clinical study management, and kit fulfillment.
Guardant Health was founded in 2011 and is based in Redwood City, California. Its shares are listed on the NASDAQ under the ticker GH.
Guardant Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.1, in the Accumulation zone, down 2.3 points over five sessions.
Down 2.3 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 21 | +4.7% | +0.7% |
| Accumulation (current zone) | 210 | +1.1% | +9.9% |
| Neutral | 400 | +2.1% | +7.5% |
| Distribution | 60 | +2.1% | +5.2% |
| Selling | 10 | −2.9% | +8.1% |
Average GH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Guardant Health trades 16.4% below Gekko Fair Value of $181.49, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Guardant Health shares are worth, recalculated every trading day.
$181.49
Gekko Fair Value, Nov 14, 2026
16.4% Undervalued
At the end of Aug 2026 the price was 12.3% below the estimate.
No open-market insider purchases were filed for Guardant Health, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for GH in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Jonathan Jackson House, IL, purchase | $15,001 - $50,000 | Oct 20 traded Sep 28 |
From congressional disclosures, which report amounts as ranges.
Guardant Health has been buying back its own shares.
From company filings.
2signals, 0% of the flagged premium in calls.
Latest: Bearish flow on Nov 3, $1.07M in unusual premium.
1of the funds Gekko tracks holds GH.
Guardant Health reports on Feb 18, 2027, after the close (95 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 18, 2027
Expected after the close, 95 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 30, 2026 | −$0.89 est −$0.74 | $335.0M est $314.2M | +12.4% |
| May 7, 2026 | −$0.45 est −$0.47 | $301.7M est $279.2M | +3.7% |
| Feb 19, 2026 | −$0.50 est −$0.77 | $281.3M est $272.4M | −4.0% |
| Oct 29, 2025 | −$0.39 est −$0.48 | $265.2M est $267.6M | +32.8% |
| Jul 30, 2025 | −$0.44 est −$0.72 | $232.1M est $235.7M | −5.4% |
| Apr 30, 2025 | −$0.49 est −$0.85 | $203.5M est $211.4M | −1.3% |
| Feb 20, 2025 | −$0.62 est −$0.50 | $201.8M est $192.5M | −12.5% |
| Nov 6, 2024 | −$0.88 est −$0.74 | $191.5M est $189.0M | +21.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Guardant Health is $200.76, +32.3% from the last close, from 19 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 19 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Piper Sandler | $190 | +25.2% |
| Nov 6 | Stifel Nicolaus | $180 | +18.7% |
| Nov 6 | Robert W. Baird | $196 | +29.2% |
| Nov 6 | RBC Capital | $200 | +31.8% |
| Nov 6 | Goldman Sachs | $210 | +38.4% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Guardant Health averaged +3.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.6% | 1 of 5 |
| Next 10 trading days | +5.8% | 5 of 5 |
| Next 15 trading days | +5.5% | 4 of 5 |
| Next 20 trading days | +3.2% | 3 of 5 |
| Next 30 trading days | −7.5% | 2 of 5 |
For scale, GH’s typical 20-trading-day move in either direction is about 11.1%.
Guardant Health’s market cap is $20.54B and revenue of $1.28B over the last twelve months.
Coverage of Guardant Health this week reads positive: 9 positive, 9 neutral and 1 negative headlines.
Guardant Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
| DVADaVita | Accumulation | 25.6% below |
A peer links to its own page where one exists.
Guardant Health’s market cap is $20.54B at the Nov 13, 2026 close of $151.70, with 135.3M shares outstanding.
The consensus analyst 12-month price target for Guardant Health is $200.76, +32.3% from the last close. Of the 19 firms that rated the stock in the last 90 days, 19 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Guardant Health is undervalued: the Nov 13, 2026 close of $151.70 is 16.4% below Gekko Fair Value of $181.49. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Guardant Health is expected to report on Feb 18, 2027, after the market closes (95 days away). Analysts expect earnings of −$0.74 per share on revenue of $370.3M. Guardant Health beat the earnings estimate in 5 of its last 8 reports, moving 11.7% on average across the report.
Guardant Health’s 52-week high is $191.05 and its 52-week low is $74.55; it closed at $151.70 on Nov 13, 2026, +55.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 2 as mixed (trend and smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Guardant Health over the last 30 days, with $0 of flagged premium in calls and $4.70M in puts. The latest, bearish flow, was on Nov 3, 2026 with $1.07M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.